Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Y-mAbs Therapeutics, Inc. Banner

Y-mAbs Therapeutics, Inc.

YMAB Stock Analysis

Page title

Section title

About Y-mAbs Therapeutics, Inc.

Biotechnology
Healthcare

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma...

Y-mAbs Therapeutics, Inc. Key Metrics

Market Cap
$605M
52 Weeks Low
$4.69
52 Weeks High
$20.90
P/B
6.27x
P/E
-24.27x
P/S
6.99x

Upcoming Events

    YMAB Analyst Forecasts

    ‌
    ‌

    YMAB Financials

    YMAB Income Statement Key Metrics

    • Revenue(TTM)86.55 M
    • Gross Profit(TTM)76.70 M
    • EBITDA(TTM)-27.17 M
    • Net Income(TTM)-24.61 M
    • EPS Diluted(TTM)-0.5626

    Decode YMAB's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    YMAB earnings and revenue history

    YMAB Return on Equity

    See how efficiently YMAB generates profit for it's shareholders.

    -21.22%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity Growth

    YMAB's Return on Equity has shown poor growth over the past 10 years, increasing by only -21.11%.

    YMAB Revenue Growth

    See how YMAB has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    YMAB's revenue has grown significantly over the past 10 years, increasing by over 0%.